Intra-cellular therapies reports q4 loss per share of $0.74

Intra-cellular therapies reports fourth quarter and full-year 2019 financial results and provides corporate update.q4 loss per share $0.74.q4 earnings per share estimate $-0.81 -- refinitiv ibes data.preparations for commercial launch of caplyta later this month are fully on track.
ITCI Ratings Summary
ITCI Quant Ranking